The world of multiple myeloma has changed considerably over the last several years, and in particular in early relapse. There are more treatment options than ever before.

Dr Joseph Mikhael discusses current best practices in treating patients with multiple myeloma in the early relapse/refractory setting and explores:
- Different treatment sequences, combinations and dosing in MM
- His experience with XPO1 inhibitors and his approach to managing side effects
Clinical Takeaways
- The treatment landscape for early relapsed multiple myeloma is expanding, including CAR-T cell therapies now available (prioritised for functional high-risk patients)
- Early relapse management involves several drug classes:
- Immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, XPO1 inhibitors
- Selinexor is a first-in-class XPO1 inhibitor. Side effects can be managed through dose modifications and with the use of antiemetics
- General principles of therapy selection include:
- Introducing a new mechanism of action
- Using a triplet combination
- Selecting the best combination based on patient, disease and treatment characteristics

This is the final video of a 3-part series.

Watch part 1 to see Dr Elena Zamagni summarise the unmet medical needs in earlier relapses in Multiple Myeloma

Watch part 2 to see Dr Fredrik Schjesvold focus on the importance of the MoA

Read more about the experts and download the accompanying slide sets on our website

Subscribe to the COR2ED YouTube channel to stay up-to-date with new medical education content as it’s released.

Come and find LYMPHOMA & MYELOMA CONNECT on social media
Follow us on LinkedIn: / lymphoma-myeloma-connect
Follow us on X: https://x.com/LYM_MM_CONNECT This content is intended for healthcare professionals only.

The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution.

This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.

This video was developed by cor2ed.com

Publication date: September 2024